By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday an increase in its grant revenues for the fourth quarter and full-year 2010, and a $140.2 million loss for the year as it prepares for the commercial launch of its PacBio RS system.

The Menlo Park, Calif.-based firm reported fourth-quarter revenues of $280,000, up from $220,000 for the fourth quarter of 2009. All of its Q4 and FY 2010 revenues are from government grants.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.